{"entity":{"id":"padmanee-sharma","kind":"person","name":"Padmanee Sharma","aka":[],"tldr":"Runs the platform that studies patients' tumours before and after immunotherapy to learn why checkpoint drugs work or fail.","summary":"Padmanee Sharma is Professor of Genitourinary Medical Oncology and Immunology and Scientific Director of the Immunotherapy Platform at MD Anderson Cancer Center. A medical oncologist and immunologist, she pioneered pre-surgical immunotherapy trials that study drug mechanisms in human tissue, examining patients' tumours before and after treatment to learn why checkpoint drugs work or fail. She co-leads the Parker Institute site at MD Anderson and the immunotherapy platform with James Allison, with work on ICOS, VISTA and resistance to checkpoint blockade. Her papers include a Cell review of primary, adaptive and acquired resistance to cancer immunotherapy and a Science perspective on the future of immune checkpoint therapy, spanning CTLA-4 and PD-1 in prostate, bladder and kidney cancer.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Padmanee_Sharma","links":[{"label":"MD Anderson faculty","url":"https://faculty.mdanderson.org/search?q=Padmanee%20Sharma"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sharma%20P%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Padmanee%20Sharma"}],"tags":[],"related":[],"cancers":["prostate","urothelial","rcc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["ctla4","pd1"],"drugs":[],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Genitourinary Medical Oncology and Immunology; Scientific Director, Immunotherapy Platform, MD Anderson","institutionId":"md-anderson","specialisms":["Immunotherapy","Genitourinary oncology","Translational immunology"],"profiles":[{"label":"MD Anderson faculty","url":"https://faculty.mdanderson.org/search?q=Padmanee%20Sharma"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sharma%20P%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Padmanee%20Sharma"}],"papers":[{"title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","journal":"Cell","year":2017,"url":"https://doi.org/10.1016/j.cell.2017.01.017","doi":"10.1016/j.cell.2017.01.017"},{"title":"The future of immune checkpoint therapy","journal":"Science","year":2015,"url":"https://doi.org/10.1126/science.aaa8172","doi":"10.1126/science.aaa8172"},{"title":"Hodi 2010: ipilimumab, the first checkpoint inhibitor, extends survival in metastatic melanoma","journal":"New England Journal of Medicine","year":2010,"url":"https://doi.org/10.1056/NEJMoa1003466","doi":"10.1056/NEJMoa1003466"},{"title":"Leach, Krummel and Allison: releasing the CTLA-4 brake makes mice reject tumours","journal":"Science","year":1996,"url":"https://doi.org/10.1126/science.271.5256.1734","doi":"10.1126/science.271.5256.1734"}]},"route":"/people/padmanee-sharma/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"ctla4","kind":"target","name":"CTLA-4","route":"/targets/ctla4/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"institution":[{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","route":"/institutions/md-anderson/"},{"id":"parker-institute","kind":"institution","name":"Parker Institute for Cancer Immunotherapy","route":"/institutions/parker-institute/"}],"paper":[{"id":"paper-hodi-ipilimumab-melanoma-nejm-2010","kind":"paper","name":"Hodi 2010: ipilimumab, the first checkpoint inhibitor, extends survival in metastatic melanoma","route":"/key-papers/paper-hodi-ipilimumab-melanoma-nejm-2010/"},{"id":"paper-leach-allison-ctla4-blockade-science-1996","kind":"paper","name":"Leach, Krummel and Allison: releasing the CTLA-4 brake makes mice reject tumours","route":"/key-papers/paper-leach-allison-ctla4-blockade-science-1996/"}]}}